Shilpa Pharma Lifesciences receives CEP from EDQM for API, Teriflunomide Ruchika Sharma24 Jan 2025 12:30 PM ISTKarnataka: Shilpa Pharma Lifesciences Limited, a 100 percent subsidiary of Shilpa Medicare Limited has received certificate of suitability (CEP)...
Teriflunomide may delay first clinical demyelinating event among patients with radiological findings of multiple sclerosis Dr. Kamal Kant Kohli27 April 2023 8:00 PM ISTRadiologically isolated syndrome is a condition which is diagnosed in people who do not have MS symptoms but who have abnormalities in the brain or...
Study: drug may delay earliest symptoms of multiple sclerosis Isra Zaman22 April 2023 9:30 AM ISTMS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves. Symptoms of MS may...
Teriflunomide delays first symptoms of multiple sclerosis Dr. Kamal Kant Kohli21 April 2023 8:15 PM ISTFrance: A preliminary study showed a drug called teriflunomide to delay the earliest symptoms of multiple sclerosis. The study's findings will be...
Ubituximab cuts relapse rate and extent of brain lesions among patients with recurrent MS: NEJM Dr. Kamal Kant Kohli30 Aug 2022 9:45 AM ISTUSA: When compared to teriflunomide, a frequently recommended oral treatment for multiple sclerosis, ubituximab, an experimental targeted B-cell...
Janssen Pharma gets USFDA nod for Ponvory to treat relapsing multiple sclerosis Ruchika Sharma21 March 2021 10:15 AM ISTNew Jersy: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (USFDA) approved PONVORY...
